Literature DB >> 7061182

Influence of dosage form and administration route on the pharmacokinetic parameters of cefadroxil.

E L Mariño, A Dominguez-Gil, C Muriel.   

Abstract

A cross-over study was utilized to compare the pharmacokinetics of 500 mg cefadroxil administered intravenously and orally in solution, suspension, and in capsule form, and to calculate its bioavailability. The antibiotic was administered to four healthy volunteers on whom four experiments were carried out. Cefadroxil was determined in serum and in urine using a microbiologic plate diffusion method. Administered intravenously the antibiotic follows a two-compartment open kinetic model, whereas orally administered, its mode is that of a single-compartment model. There are no statistically significant differences between the parameters defining the elimination of the antibiotic in the four groups studied.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7061182

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  4 in total

1.  Dose-dependent absorption and elimination of cefadroxil in man.

Authors:  T M Garrigues; U Martin; J E Peris-Ribera; L F Prescott
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  In vivo absorption and disposition of cefadroxil after escalating oral doses in wild-type and PepT1 knockout mice.

Authors:  Maria M Posada; David E Smith
Journal:  Pharm Res       Date:  2013-11       Impact factor: 4.200

3.  Pharmacokinetics of cefmetazole administered intramuscularly and intravenously to healthy adults.

Authors:  J Rodriguez-Barbero; E L Mariño; A Dominguez-Gil
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

Review 4.  Role of cephalosporins in the era of Clostridium difficile infection.

Authors:  Mark H Wilcox; James D Chalmers; Carl E Nord; Jane Freeman; Emilio Bouza
Journal:  J Antimicrob Chemother       Date:  2016-09-22       Impact factor: 5.790

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.